Clinical trials for the verification of safety and efficiency of tamibarotene for the treatment of Alzheimer's disease

Clinical trials for the verification of safety and efficiency of tamibarotene for the treatment of Alzheimer's disease - Clinical trials of tamibarotene for Alzheimer's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2090220288

Enrollment

Registered

2017-04-13

Start date

2017-04-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

Intervention type: Name of intervention:Tamibariotene Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application: Dose per administration:4mg Dosing frequenc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients of Alzheimer's disease with mild and moderate cognitive disfunction(15<MMSE score<27)

Exclusion criteria

Exclusion criteria: The use of other drugs of clinical trials

Design outcomes

Primary

Measure	Time frame
Cognitive function scores (ADAS-JCog, MMSE, CIBIC-plus, ADCS-ADL)and safety	—

Contacts

Public ContactFumihiko Yasuno

Nara Medical University

yasunof@naramd-u.ac.jp+81-744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026